Who's Watching The Watchmen This Time? The Mystery Of The New IRB Sting
This article was originally published in The Pink Sheet Daily
Executive Summary
Institutional review boards appear to be facing vigilante regulation as FDA warns that someone is submitting fictitious studies for review.
You may also be interested in...
IRBs Punked Again: FDA Sends Warning Letter To Essex IRB For Approving Fictitious Trial
In an operation highly reminiscent of a government sting three and a half years ago, "Dateline NBC" snares a for-profit IRB using a fictitious protocol.
IRBs Punked Again: FDA Sends Warning Letter To Essex IRB For Approving Fictitious Trial
In an operation highly reminiscent of a government sting three and a half years ago, "Dateline NBC" snares a for-profit IRB using a fictitious protocol.
IRB Quality Concerns Take Center Stage After FDA Clamps Down On Coast
Quality has moved up in importance as a criterion for selecting an institutional review board following an April 14 FDA warning letter to Coast IRB and the company's agreement to halt enrollment in clinical studies it monitors